Related Experiment Videos
[Rationale for Herceptin in the clinical use]
Hiromichi Ebi1, Yasutsuna Sasaki
1Division of Hematology/Oncology, National Cancer Center Hospital East.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 22, 2002
Summary
Human epidermal growth factor receptor-2 (HER2) targeted therapy, trastuzumab, shows efficacy in HER2-overexpressing cancers. Combination with anthracyclines increases cardiac toxicity risk, warranting further investigation.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Context:
- Human epidermal growth factor receptor-2 (HER2) overexpression is prevalent in various cancers, correlating with aggressive disease and poor prognosis.
- Trastuzumab is a humanized monoclonal antibody targeting the extracellular domain of HER2.
- HER2 amplification drives tumor growth and is a validated therapeutic target.
Purpose:
- To evaluate the efficacy and safety of trastuzumab in HER2-overexpressing cancers.
- To assess trastuzumab's role as a single agent and in combination chemotherapy.
- To investigate potential toxicities associated with trastuzumab-based regimens.
Summary:
- Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells in vitro and mediates antibody-dependent cellular toxicity.
- Clinical trials confirm trastuzumab's effectiveness in recurrent/metastatic breast cancer with HER2 overexpression.
- Combination therapy with anthracyclines revealed a high incidence of cardiac toxicity.
Impact:
- Trastuzumab represents a significant advancement in targeted therapy for HER2-positive cancers.
- Identifies a critical safety concern regarding cardiotoxicity when combined with anthracyclines.
- Highlights the need for ongoing research into optimal combination strategies and expanded indications for trastuzumab.